Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04116073 · ClinicalTrials.gov registry record · Phase 2
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
A Phase 2 study of Pancreatic Cancer Metastatic and Pancreatic Cancer Non-resectable, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04116073 is a Phase 2 study of Pancreatic Cancer Metastatic and Pancreatic Cancer Non-resectable that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 25 participants, below the 129-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04116073, a Phase 2 study of Pancreatic Cancer Metastatic and Pancreatic Cancer Non-resectable, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
Conditions Studied
Interventions
- DRUG INCMGA00012 (PD-1 antibody)
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04116073
The ClinicalTrials.gov registry entry for NCT04116073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (81% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which INCMGA00012 (PD-1 antibody) is the first listed.
NCT04116073 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04116073 about?
NCT04116073 is a clinical study titled "INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer". Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
What is the current status of trial NCT04116073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-04-09. Estimated completion is 2024-12-03.
What conditions does trial NCT04116073 study?
This clinical trial studies the following conditions: Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable.
What interventions are being tested in trial NCT04116073?
The interventions under investigation include: INCMGA00012 (PD-1 antibody) (DRUG).
Who is sponsoring clinical trial NCT04116073?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04116073 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
COMPLETED · Phase 2
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RECRUITING · Phase 1
-
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Pancreatic Cancer Metastatic
All registered trials for this condition
Pancreatic Cancer Non-resectable
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.